New Class of Drug Treats Heart Disease, Diabetes

Researchers at the University of Alberta have developed a synthetic peptide that could be the first in a new class of drugs
Sept. 19, 2013

Researchers at the U of A found that a deficiency in the peptide apelin is associated with heart failure, pulmonary hypertension and diabetes. They also developed a synthetic version that targets pathways in the heart and promotes blood vessel growth. Read the full story.

Sign up for Pharma Manufacturing Newsletters
Get the latest news and updates